- Home
- / Barinthus Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Barinthus Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.5
2024-10-29
Market Capitalization
$57.2 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 268.0K | 44.7M | 802.0K | 15.0M | |
| Gross profit | 600.0K | 45.3M | 1.9M | 16.1M | 16.0K |
| Gross profit margin, % | 223.9% | 101.3% | 234.9% | 107.9% | |
| Operating expense total | 40.9M | 43.5M | 75.8M | 62.8M | 54.8M |
| Depreciation and amortization | 602.0K | 4.3M | 5.4M | 18.0M | 10.6M |
| EBITDA | (40.3M) | 1.7M | (73.9M) | (46.6M) | (54.7M) |
| EBITDA margin, % | -15032.1% | 3.9% | -9219.7% | -311.5% | |
| EBIT | (54.7M) | (2.6M) | (79.4M) | (64.5M) | (64.8M) |
| EBIT margin, % | -20401.9% | -5.8% | -9896.6% | -430.9% | |
| Interest income | 2.0K | 3.1M | 2.9M | 2.7M | 2.0M |
| Interest expense | 2.7M | 19.0K | 28.0K | 53.0K | 51.0K |
| Pre tax profit | (51.1M) | 850.0K | (76.5M) | (61.2M) | (66.6M) |
| Income tax expense | (28.0K) | (4.5M) | (3.1M) | (44.0K) | (175.0K) |
| Net Income | (51.1M) | 5.3M | (73.4M) | (61.2M) | (66.5M) |